Translational research in central nervous system drug discovery.
about
The lonely mouse - single housing affects serotonergic signaling integrity measured by 8-OH-DPAT-induced hypothermia in male miceInfluence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometryEmerging pharmacotherapy of tinnitus.ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspectiveUsing NMR approaches to drive the search for new CNS therapeutics.Developing therapeutics for the treatment of multiple sclerosisQuantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisThe effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome.Translational research: current status, challenges and future strategies.Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and SchizophreniaMedications development to treat alcohol dependence: a vision for the next decade.Randomized, Blinded Pilot Testing of Nonconventional Stimulation Patterns and Shapes in Parkinson's Disease and Essential Tremor: Evidence for Further Evaluating Narrow and Biphasic Pulses.Cell therapy: the final frontier for treatment of neurological diseases.Utility of CSF in translational neuroscience.Conotoxin therapeutics: a pipeline for success?Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.Studying human disease using human neurons.NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.Towards a more robust approach to selecting and prosecuting promising targets and compounds.What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosisHas the time come for predictive computer modeling in CNS drug discovery and development?The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials.A portfolio-based approach to optimize proof-of-concept clinical trials.Commentary: Establishing zebrafish as a model to study the anxiolytic effects of scopolamine.Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling
P2860
Q27334197-01C6C4B5-DA6D-4344-9F3C-BB39216C4A0CQ30404054-E52E7E51-B4E8-446A-982C-D9CB86606AFDQ30478378-8AAF9DF7-7A63-4B53-95E6-E8097553CED0Q33469822-F42B1F1E-783E-407F-8301-E556B2559CE9Q33613767-8BD87CC9-13E5-4BBB-839D-D9371DD0F71FQ33946995-B806A7BD-1A17-4D9B-99D1-EA3AA508E38EQ34323711-171EE00B-7D8A-4FBC-B823-117FE798D4CCQ34459374-3EA73B4A-947A-40BB-A535-B66ADC8C9945Q35341956-4C564A95-103D-4FED-A168-1118F44EA5C2Q35485519-CF5F399B-7D65-4327-A105-DABA7AF749E3Q36063627-BEC829BB-B84F-427E-8659-08C176A81C86Q36357552-152BF03B-2D71-4EE4-B018-33BD0ACB0276Q37022707-EFF65BFF-5531-424B-A0AE-7826B147079DQ38068560-A0439127-BAD4-4AAA-B239-CEC06A168056Q38080762-CFAD550B-7F21-4DA4-A858-3341F2361403Q38088765-B3592335-F8B8-46BE-A46B-6E8241ED970EQ38351399-F71BD73B-5280-41C3-B57C-61DBB5EBA6F7Q38676860-0DBF32B4-4DA1-4743-9629-9FA787D2D00CQ38802823-9B7C66B5-4537-4001-BD8C-789DB71EFD00Q38962399-A018B0E8-6A89-4605-814C-C4FA7DDCEA89Q39915228-E1BED06F-0B66-4E1A-9B3C-91A7C3EEB09BQ40055789-745DF120-0EC1-4DFD-BCB7-B55ACFE3C62FQ41865521-BA3A5815-D04D-41E4-A9FE-4B30DAB87AD5Q42097007-D05B91D8-009F-447F-A716-E2773769F321Q43795136-E6E68840-89C2-431D-ADE2-DB60FB7D7BFAQ44644308-8B1E5257-4AD4-44E6-95F8-AF506A0728A4Q52581120-244C5B3D-DE74-4A0E-A0DB-E02D0B9DEC85Q58780116-0AE30011-19B6-492F-B260-141811D4555E
P2860
Translational research in central nervous system drug discovery.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Translational research in central nervous system drug discovery.
@ast
Translational research in central nervous system drug discovery.
@en
type
label
Translational research in central nervous system drug discovery.
@ast
Translational research in central nervous system drug discovery.
@en
prefLabel
Translational research in central nervous system drug discovery.
@ast
Translational research in central nervous system drug discovery.
@en
P2860
P356
P1433
P1476
Translational research in central nervous system drug discovery.
@en
P2093
John L Ryan
Orest Hurko
P2860
P304
P356
10.1602/NEURORX.2.4.671
P577
2005-10-01T00:00:00Z